Abstract
The management of severe, refractory chronic pain remains a major unmet clinical need, complicated by opioid limitations and the narrow therapeutic window of intrathecal ziconotide, a selective N-type voltage-gated calcium channel (CaV2.2) blocker. A recent study by Jin et al. provides the first in vivo evidence that spinal neuropeptide FF (NPFF) receptor signaling functionally cross-talks with CaV2.2 to enhance ziconotide-evoked antinociception without inducing tolerance. This commentary integrates advances in GPCR-ion channel crosstalk, receptor subtype pharmacology, and translational pain medicine. We discuss that NPFF-based combinatorial strategies can enhance ziconotide’s analgesic efficacy, potentially allowing a reduction in ziconotide dosage to mitigate its neurological side effects and thereby inform the development of novel combinatorial analgesic strategies for clinically accessible intrathecal delivery. We also highlight unresolved questions regarding NPFF1/NPFF2 subtype contributions, cell-type-specific signaling, and translatability to human pathological pain. The NPFF-CaV2.2 axis represents a promising target to revolutionize non-opioid pain pharmacotherapy.
Keywords
Neuropeptide FF, Ziconotide, CaV2.2 channel, Pain, GPCR-ion channel crosstalk